1 / 10

28th Annual San Antonio Breast Cancer Symposium December 8-11, 2005; San Antonio, Texas

28th Annual San Antonio Breast Cancer Symposium December 8-11, 2005; San Antonio, Texas. Angiogenic Therapy for Breast Cancer. Summarized by Kathy Miller, MD Indiana University School of Medicine Indianapolis, Indiana. Supported by an unrestricted educational grant from.

rane
Download Presentation

28th Annual San Antonio Breast Cancer Symposium December 8-11, 2005; San Antonio, Texas

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 28th Annual San Antonio Breast Cancer SymposiumDecember 8-11, 2005; San Antonio, Texas Angiogenic Therapy for Breast Cancer Summarized byKathy Miller, MDIndiana University School of MedicineIndianapolis, Indiana Supported by an unrestricted educational grant from

  2. E2100: A Randomized Phase 3 Trial of Paclitaxel vs Paclitaxel + Bevacizumab for Advanced Breast Cancer • Stratify: • DFI < 24 months vs > 24 months • < 3 vs > 3 metastatic sites • Adjuvant chemotherapy, yes vs no • ER+ vs ER- vs ER-unknown RANDOMI ZE Paclitaxel + Bevacizumab 28-day cycle: Paclitaxel 90 mg/m2 D1, 8, and 15 Bevacizumab 10 mg/kg D1 and 15 Paclitaxel Miller et al. Breast Cancer Res Treat. 2005;95(suppl 1):S6. Abstract 3.

  3. E2100: Patient Characteristics Milleret al. Breast Cancer Res Treat. 2005;95(suppl 1):S6. Abstract 3.

  4. P < .0001 P < .0001 E2100: Response 37.7% 29.9% 16% 13.8% 339 341 262 236 Miller et al. Breast Cancer Res Treat. 2005;95(suppl 1):S6. Abstract 3.

  5. Pac + Bev 11.4 months 1.0 Paclitaxel 6.11 months 0.8 0.6 PFS Probability 0.4 0.2 0.0 0 6 12 18 24 30 Months E2100: Progression-Free Survival HR = 0.51 (0.43-0.62) Log Rank Test P <0 .0001 484 events reported Miller et al. Breast Cancer Res Treat. 2005;95(suppl 1):S6. Abstract 3.

  6. E2100: Bevacizumab ToxicityNCI-CTC Grade 3 and 4 *Toxicities significantly increased with bevacizumab Miller et al. Breast Cancer Res Treat. 2005;95(suppl 1):S6. Abstract 3.

  7. E2104 Adjuvant Pilot Trial Arm A:dose-dense BAC > BT > B R E G I S T E R Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 Bevacizumab 10 mg/kg every 14 days x 4 Paclitaxel 175 mg/m2Bevacizumab 10 mg/kg every 14 days x 4 Bevacizumab 10 mg/kg every 14 days x 18 Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 every 14 days x 4 Paclitaxel 175 mg/m2Bevacizumab 10 mg/kg every 14 days x 4 Bevacizumab 10 mg/kg every 14 days x 22 Arm B: dose-dense AC >BT>B *Hormone therapy and radiation per standard care

  8. Randomized Phase 2 Trial of Metronomic Chemotherapy +/- Bevacizumab CM alone Cyclophosphamide 50 mg orally, daily Methotrexate 2.5 mg orally, twice a day, days 1, 2 each week < 1 prior chemo for MBC R Option of crossover upon progression CM + bevacizumab Cyclophosphamide 50 mg orally,daily Methotrexate 2.5 mg orally, twice a day,days 1, 2 each week Bevacizumab 10 mg/kg intravenously every 14 days Burstein et al. Breast Cancer Res Treat. 2005;94(suppl 1):S6. Abstract 4.

  9. Phase 2 Metronomic CM vs CM + Bevacizumab: Patient Characteristics Burstein et al. Breast Cancer Res Treat. 2005;94(suppl 1):S6. Abstract 4.

  10. Phase 2 Metronomic CM vs CM + Bevacizumab: Best Overall Response Burstein et al. Breast Cancer Res Treat. 2005;94(suppl 1):S6. Abstract 4.

More Related